Design and evaluation of a novel transdermal patch containing diclofenac and teriflunomide for rheumatoid arthritis therapy

The aim of this study was to design a compound transdermal patch containing diclofenac (DA) and teriflunomide (TEF) for the treatment of rheumatoid arthritis (RA). The various organic amines salts of DA were prepared and their forming was confirmed using DSC and FTIR. The percutaneous permeation of...

Full description

Bibliographic Details
Main Authors: Yuxiu Zhang, Dongmei Cun, Xin Kong, Liang Fang
Format: Article
Language:English
Published: Elsevier 2014-10-01
Series:Asian Journal of Pharmaceutical Sciences
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1818087614000658
id doaj-ed85ac1a121d4024b7361f6cd19f54d3
record_format Article
spelling doaj-ed85ac1a121d4024b7361f6cd19f54d32020-11-24T20:47:31ZengElsevierAsian Journal of Pharmaceutical Sciences1818-08762014-10-019525125910.1016/j.ajps.2014.07.007Design and evaluation of a novel transdermal patch containing diclofenac and teriflunomide for rheumatoid arthritis therapyYuxiu ZhangDongmei CunXin KongLiang FangThe aim of this study was to design a compound transdermal patch containing diclofenac (DA) and teriflunomide (TEF) for the treatment of rheumatoid arthritis (RA). The various organic amines salts of DA were prepared and their forming was confirmed using DSC and FTIR. The percutaneous permeation of organic amines salt of DA was investigated in vitro using a two-chamber diffusion cell with excised rabbit skin as transdermal barrier. The formulation of the patch was optimized in terms of the concentration of percutaneous permeation enhancer and the loading dose of drugs. The pharmacokinetic behavior of the optimal formulation was studies in rabbits and the anti-inflammatory and analgesic effects of the optimal patch were evaluated with the adjuvant arthritis model in rats and the pain model in mice, respectively. The result showed that skin penetration of diclofenac-triethylamine (DA-TEtA) salt was better than other organic amine salts. Based on previous study of our laboratory, teriflunomide-triethylamine (TEF-TEtA) significantly enhanced the skin permeation of TEF. 10% of azone (AZ) was the best enhancer for the two drugs. The optimal patch formulation was composed of 2% of TEF-TEtA, 6% of DA-TEtA and 10% of AZ. The cumulative permeated amount of DA-TEtA in vitro was comparable with that of the commercial diclofenac-diethylamine (DA-DEtA) patch. The absolute bioavailability of TEF-TEtA was 42%, which could achieve the therapeutic drug levels. In animal study, the optimized compound patch containing DA-TEtA and TEF-TEtA displayed significant anti-inflammatory and analgesic effect, which indicated the potential of the compound patch.http://www.sciencedirect.com/science/article/pii/S1818087614000658Diclofenac (DA)Teriflunomide (TEF)Organic amine saltsPatchRheumatoid arthritis (RA)Pharmacodynamics
collection DOAJ
language English
format Article
sources DOAJ
author Yuxiu Zhang
Dongmei Cun
Xin Kong
Liang Fang
spellingShingle Yuxiu Zhang
Dongmei Cun
Xin Kong
Liang Fang
Design and evaluation of a novel transdermal patch containing diclofenac and teriflunomide for rheumatoid arthritis therapy
Asian Journal of Pharmaceutical Sciences
Diclofenac (DA)
Teriflunomide (TEF)
Organic amine salts
Patch
Rheumatoid arthritis (RA)
Pharmacodynamics
author_facet Yuxiu Zhang
Dongmei Cun
Xin Kong
Liang Fang
author_sort Yuxiu Zhang
title Design and evaluation of a novel transdermal patch containing diclofenac and teriflunomide for rheumatoid arthritis therapy
title_short Design and evaluation of a novel transdermal patch containing diclofenac and teriflunomide for rheumatoid arthritis therapy
title_full Design and evaluation of a novel transdermal patch containing diclofenac and teriflunomide for rheumatoid arthritis therapy
title_fullStr Design and evaluation of a novel transdermal patch containing diclofenac and teriflunomide for rheumatoid arthritis therapy
title_full_unstemmed Design and evaluation of a novel transdermal patch containing diclofenac and teriflunomide for rheumatoid arthritis therapy
title_sort design and evaluation of a novel transdermal patch containing diclofenac and teriflunomide for rheumatoid arthritis therapy
publisher Elsevier
series Asian Journal of Pharmaceutical Sciences
issn 1818-0876
publishDate 2014-10-01
description The aim of this study was to design a compound transdermal patch containing diclofenac (DA) and teriflunomide (TEF) for the treatment of rheumatoid arthritis (RA). The various organic amines salts of DA were prepared and their forming was confirmed using DSC and FTIR. The percutaneous permeation of organic amines salt of DA was investigated in vitro using a two-chamber diffusion cell with excised rabbit skin as transdermal barrier. The formulation of the patch was optimized in terms of the concentration of percutaneous permeation enhancer and the loading dose of drugs. The pharmacokinetic behavior of the optimal formulation was studies in rabbits and the anti-inflammatory and analgesic effects of the optimal patch were evaluated with the adjuvant arthritis model in rats and the pain model in mice, respectively. The result showed that skin penetration of diclofenac-triethylamine (DA-TEtA) salt was better than other organic amine salts. Based on previous study of our laboratory, teriflunomide-triethylamine (TEF-TEtA) significantly enhanced the skin permeation of TEF. 10% of azone (AZ) was the best enhancer for the two drugs. The optimal patch formulation was composed of 2% of TEF-TEtA, 6% of DA-TEtA and 10% of AZ. The cumulative permeated amount of DA-TEtA in vitro was comparable with that of the commercial diclofenac-diethylamine (DA-DEtA) patch. The absolute bioavailability of TEF-TEtA was 42%, which could achieve the therapeutic drug levels. In animal study, the optimized compound patch containing DA-TEtA and TEF-TEtA displayed significant anti-inflammatory and analgesic effect, which indicated the potential of the compound patch.
topic Diclofenac (DA)
Teriflunomide (TEF)
Organic amine salts
Patch
Rheumatoid arthritis (RA)
Pharmacodynamics
url http://www.sciencedirect.com/science/article/pii/S1818087614000658
work_keys_str_mv AT yuxiuzhang designandevaluationofanoveltransdermalpatchcontainingdiclofenacandteriflunomideforrheumatoidarthritistherapy
AT dongmeicun designandevaluationofanoveltransdermalpatchcontainingdiclofenacandteriflunomideforrheumatoidarthritistherapy
AT xinkong designandevaluationofanoveltransdermalpatchcontainingdiclofenacandteriflunomideforrheumatoidarthritistherapy
AT liangfang designandevaluationofanoveltransdermalpatchcontainingdiclofenacandteriflunomideforrheumatoidarthritistherapy
_version_ 1716809731607101440